BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 32449811)

  • 1. Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration-resistant prostate cancer cells via altering androgen receptor-lectin-like transcript 1 signals.
    Tang M; Gao S; Zhang L; Liu B; Li J; Wang Z; Zhang W
    Prostate; 2020 Jul; 80(10):742-752. PubMed ID: 32449811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
    Shi L; Lin H; Li G; Sun Y; Shen J; Xu J; Lin C; Yeh S; Cai X; Chang C
    Cancer Lett; 2016 Apr; 373(1):45-56. PubMed ID: 26805759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9® led to increase docetaxel sensitivity via suppressing the p21 expression.
    Luo J; Tian J; Chou F; Lin C; Xing EZ; Zuo L; Niu Y; Yeh S; Chang C
    Cancer Lett; 2019 Mar; 444():35-44. PubMed ID: 30248372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer cells inhibits NK cell-mediated killing through LLT1-NKRP1A (CD161) interaction.
    Mathew SO; Chaudhary P; Powers SB; Vishwanatha JK; Mathew PA
    Oncotarget; 2016 Oct; 7(42):68650-68661. PubMed ID: 27626681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
    Lin SJ; Chou FJ; Li L; Lin CY; Yeh S; Chang C
    Cancer Lett; 2017 Jul; 398():62-69. PubMed ID: 28373004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor (AR) degradation enhancer ASC-J9
    Cheng MA; Chou FJ; Wang K; Yang R; Ding J; Zhang Q; Li G; Yeh S; Xu D; Chang C
    Cancer Lett; 2018 Mar; 417():182-191. PubMed ID: 29203251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
    Wang R; Lin W; Lin C; Li L; Sun Y; Chang C
    Cancer Lett; 2016 Aug; 379(1):154-60. PubMed ID: 27233475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer.
    Park SE; Kim HG; Kim DE; Jung YJ; Kim Y; Jeong SY; Choi EK; Hwang JJ; Kim CS
    Invest New Drugs; 2018 Apr; 36(2):195-205. PubMed ID: 29110173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.
    Pilling A; Kim SH; Hwang C
    Prostate; 2022 Feb; 82(2):182-192. PubMed ID: 34672379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer.
    Mout L; Moll JM; Chen M; de Morrée ES; de Ridder CMA; Gibson A; Stuurman D; Aghai A; Erkens-Schulze S; Mathijssen RHJ; Sparreboom A; de Wit R; Lolkema MP; van Weerden WM
    Br J Cancer; 2020 Dec; 123(12):1715-1719. PubMed ID: 32989230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells.
    Liu L; Lou N; Li X; Xu G; Ruan H; Xiao W; Qiu B; Bao L; Yuan C; Huang X; Wang K; Cao Q; Chen K; Yang H; Zhang X
    Oncol Rep; 2017 Jun; 37(6):3651-3659. PubMed ID: 28498452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
    Komura K; Jeong SH; Hinohara K; Qu F; Wang X; Hiraki M; Azuma H; Lee GS; Kantoff PW; Sweeney CJ
    Proc Natl Acad Sci U S A; 2016 May; 113(22):6259-64. PubMed ID: 27185910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
    Xu L; Shen M; Chen X; Zhu R; Yang DR; Tsai Y; Keng PC; Chen Y; Lee SO
    Prostate; 2018 Apr; 78(5):353-364. PubMed ID: 29330929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
    Shiota M; Kashiwagi E; Yokomizo A; Takeuchi A; Dejima T; Song Y; Tatsugami K; Inokuchi J; Uchiumi T; Naito S
    Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels.
    Xu L; Chen X; Shen M; Yang DR; Fang L; Weng G; Tsai Y; Keng PC; Chen Y; Lee SO
    Mol Oncol; 2018 Mar; 12(3):269-286. PubMed ID: 28865178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dose androgen suppresses natural killer cytotoxicity of castration-resistant prostate cancer cells via altering AR/circFKBP5/miRNA-513a-5p/PD-L1 signals.
    Tang M; Sun Y; Huang CP; Chen L; Liu B; You B; Wang Z; Chang C
    Cell Death Dis; 2022 Aug; 13(8):746. PubMed ID: 36038573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants.
    Isharwal S; Modi S; Arora N; Uhlrich C; Giri B; Barlass U; Soubra A; Chugh R; Dehm SM; Dudeja V; Saluja A; Banerjee S; Konety B
    Prostate; 2017 May; 77(6):584-596. PubMed ID: 28144973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ferroptosis inducer erastin downregulates androgen receptor and its splice variants in castration‑resistant prostate cancer.
    Yang Y; Liu T; Hu C; Xia H; Liu W; Chen J; Wu S; Jiang Y; Xu Y; Liu W; Zhao L
    Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer.
    Wang F; Wu L; Yin L; Shi H; Gu Y; Xing N
    Clin Transl Med; 2022 Jun; 12(6):e901. PubMed ID: 35696531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.